Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc.

TRVI · Nasdaq

Trevi Therapeutics, Inc. (TRVI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Trevi Therapeutics, Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 82 days

EPS estimate

-0.13

Revenue estimate

0

Past earnings

06 Aug 2026
EPS actual
-0.11 (-0.5%)
estimate -0.11
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
05 May 2026
EPS actual
-0.09 (-19.0%)
estimate -0.08
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
17 Mar 2026
EPS actual
-0.06 (+37.9%)
estimate -0.10
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 Nov 2025
EPS actual
-0.08 (+18.6%)
estimate -0.10
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Trevi Therapeutics, Inc. missed consensus on EPS in its latest report, with EPS of USD -0.11 versus an estimate of USD -0.1095, while revenue met expectations at USD 0. In the prior quarter EPS also missed expectations and revenue likewise met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Jennifer L. Good
Employees
31
IPO date
07 May 2019
ISIN
US89532M1018
Website
trevitherapeutics.com

Frequently asked questions

When does Trevi Therapeutics, Inc. (TRVI) next report earnings?

Trevi Therapeutics, Inc. (TRVI) is scheduled to report earnings on November 11, 2026.

What was Trevi Therapeutics, Inc.'s most recent earnings date?

Trevi Therapeutics, Inc. (TRVI) last reported earnings on August 6, 2026.

Where is Trevi Therapeutics, Inc. stock listed?

Trevi Therapeutics, Inc. (TRVI) is listed on Nasdaq.